Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448
Stopped Developing new formulation of study drug. New study to open next year under a new protocol.
Conditions
- Prostate Cancer
- Prostatic Neoplasms
Interventions
- DRUG: Leuprorelin
- DRUG: TAK-448
Sponsor
Millennium Pharmaceuticals, Inc.